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Introduction
Several studies (1) (2) (3) have demonstrated a prolonged and sustained progression free-survival (PFS) in patients with relapsed follicular lymphoma (FL) treated with high-dose therapy (HDT) and autologous stem cell rescue (ASCR), supporting the notion that a subset of patients with FL might be cured with HDT-ASCR. The difficulty lies in determining the best timing for this procedure, given its toxicity, especially long term. (3) This task has become even more difficult since the advent of alternative therapeutic options. Maintenance with rituximab in second remission results in a prolonged PFS and, in some studies, in an improved OS, (4) (5) (6) (7) regardless of whether patients receive rituximab as part of the salvage treatment or not. However, there is no plateau in the PFS curves and hence no indication that this strategy will result in the cure of FL (this notwithstanding the impact that rituximab has made in the outcome of patients with FL). In parallel, the advent of reducedintensity conditioning (RIC) regimens has significantly decreased the treatmentrelated mortality associated with allogeneic transplant and, thus, has broadened the indications for this approach, generally regarded as the only treatment potentially curative for patients with FL so far. (8) The best results reported for HDT-ASCR have been achieved in patients treated in first or second remission.(1, 3) However, some patients might not accept the potential toxicity of this procedure so early in the course of the disease, particularly in view of the reported success of maintenance with rituximab. The main reasons to proceed to HDT-ASCR in second remission rather than at a later response are to decrease the amount of therapy received by patients prior to HDT-ASCR and to perform the procedure at the time when a good response has been achieved, which might not be possible when the subsequent recurrence happens.
Patients with chemo-sensitive recurrent FL who received HDT with a total-body irradiation (TBI)-conditioning regimen had a significantly prolonged response duration in comparison with historical controls,(1) but this was offset by an increased risk of secondary malignancies, especially secondary myelodysplastic syndromes (sMDS), likely to be related (at least partially) to the use of TBI.(3) This prompted some centers to abandon TBI-conditioning regimens in favor of chemotherapy-only containing regimens such as BEAM (BCNU, etoposide, cytarabine, melphalan). The number of prior treatment lines seemed to have also an impact on the outcome in patients treated with a TBI-conditioning regimen, with a shorter OS for patients treated beyond second response or having received 3 or more previous lines of treatment.(1) This is indeed the rationale favoring an allogeneic transplant over HDT/ASCR in patients in third remission who had not received HDT-ASCR. It is not known, however, whether the number of previous treatment lines also impairs the outcome of patients treated with BEAM, a, theoretically, less leukemogenic regimen, but this information might be important to decide the best timing for such procedure. This is relevant at a time when patients with FL who did not receive immunochemotherapy as first-line treatment are presenting with disease progression. Table 1 . Thirty patients had tFL diagnosed by a tissue biopsy at the episode of disease leading to HDT. High-dose therapy was administered in 14 patients (17%) in first remission: in 11 because more than one line of treatment was required to attain at least a partial response and in 3 because of histological transformation after initial expectant management. The remainder of the patients had HDT in second or subsequent remission. Thirty-eight patients (47%) had received rituximab prior to HDT, in 1 as part of the first-line therapy, in 28 as part of the salvage regimen before BEAM, and in 4 as part of the conditioning regimen for in vivo purging before BEAM (in the setting of a clinical trial). There was a trend toward a higher use of rituximab before BEAM in patients who had HDT for FL (56%) in comparison with those who had BEAM for tFL (33%, p=0.05).
Design and methods

Eligibility for HDT
High dose therapy
All patients received the chemotherapy-only conditioning regimen BEAM (BCNU, etoposide, cytarabine, melphalan) as previously described. 
Definitions and statistical analysis
Response was categorized according to local criteria used at the time. (11, 12) Complete response (CR) was defined as in the consensus statement,(13) 'good partial remission' (GPR) is broadly comparable to CR uncertain (CRu) and 'poor PR'
(PPR) to partial response (PR). An 'episode' of disease was defined as recurrence (in patients in CR) or progression (in patients in PR) after achievement of best response -irrespective of the number of lines of treatment needed. Overall survival (OS) was measured from date of HDT to date of last follow-up or death(13) and time to progression (TTP) was defined as the time from HDT until documented lymphoma progression or death as a result of lymphoma. (14) Survival analysis was performed by the Kaplan-Meier(15) method using the log-rank statistic (16) to test for significant associations where appropriate. The risk of sMDS was calculated using cumulative incidence (CI) rates taking into account the competing risk structure. Median follow-up was calculated for patients alive at last follow-up only.
Informed consent and IRB approval was obtained to collect and store all patient information and perform analysis.
Follow-up
Patients were followed-up monthly for the first 3 months, quarterly for 3 years, 
Results
Relapse and time to progression
After a median follow-up of 76 months (range: 14-160), 43 patients have had disease progression at a median time of 12 months (range: 3-77). The median time to progression was significantly longer for patients who had FL (16 months) than for those who had tFL at the recurrence immediately prior to HDT (7 months, p=0.0003).
A biopsy was performed at relapse after BEAM in 38 patients and demonstrated FL in 19 cases, tFL in 15 cases and non-Hodgkin lymphoma (non-specified subtype) in 4. Table 2 summarizes the results of the biopsies after BEAM.
Five-year TTP was 44% (95% confidence interval -CI-: 33-55%) (Figure 1 ).
TTP at 5 years was 49% (95%CI: 30-66%) for patients who had received 1 or 2 lines of treatment before BEAM, in comparison with 41% (95%CI: 27-55%) for those who had received 3 or more prior treatment lines (p=NS) (Figure 2 ). There were no statistically significant differences in TTP according to the length of the response prior to BEAM (5-year TTP: 44 versus 46% for patients with a response duration <1.5 years and >1.5 years, respectively, p=NS). TTP according to other potential prognostic factors is shown in Table 3 .
Secondary myelodysplastic syndromes
Three patients were diagnosed with sMDS after BEAM, the CI of sMDS being 5% at 5 and 10 years. Table 1s details the results of triple FISH pre-HDT and the treatments the patients received prior to the diagnosis of sMDS.
Causes of death and overall survival
Twenty shown in Figure 3 . Table 3 shows OS according to other potential risk factors. In summary, this study demonstrates that, HDT with BEAM is still a safe procedure in patients in third remission of FL, as this does not compromise their outcome. In the current era of rituximab and RIC regimens, the appropriate timing for HDT in relapsed FL remains to be defined. It might be that there is not an 'appropriate timing' for HDT in FL, but that, in some specific situation or circumstances, HDT is the best option. The challenge lies in defining what these specific circumstances are. It is hoped that this question will be answered definitively by a randomized clinical trial, although we are pessimistic about this happening in the near future, given the economic costs and other significant difficulties involved. In this setting, this study adds important information that needs to be considered when offering HDT to patients with relapsed FL.
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